適應症
利用體外核酸增幅試驗,定量檢測人類血漿(EDTA血漿)中之第一型人類免疫缺乏病毒(HIV-1)之RNA含量。  
劑型
 
包裝
48 Tests P/N: 05212294 190 
許可證字號
衛部藥製字第021921號 
註銷狀態
註銷日期
 
註銷理由
 
有效日期
2025-12-07  
發證日期
2010-12-07  
許可證種類
09 
中文品名
羅氏全自動達可愛滋病毒量核酸檢驗套組第2代 
英文品名
COBAS® AmpliPrep/COBAS® TaqMan® HIV-1 Test, version 2.0 
藥品類別
B 血液學及病理學裝置 
申請商地址
臺北市中山區民權東路3段2號10樓 
通關簽審文件編號
DHA00602192108 
資料更新時間
 
製造商
名稱 廠址 公司地址 國別 製程
ROCHE MOLECULAR SYSTEMS, INC. 1080 US HIGHWAY 202 SOUTH BRANCHBURG, NJ 08876, USA US {"value":"P01","name":"Manufactured by"}, {"value":"P01","name":"Manufactured by"}
成份表
處方標示 成分名稱 含量 單位
1 COBAS® AmpliPrep/COBAS® TaqMan® 48 Tests\nHIV-1 Test, v2.0\n (P/N: 05212294 190) \n
1 HIV-1 v2.0 CS1 1 x 48 Tests\n(HIV-1 Magnetic Glass Particles Reagent Cassette) \nMagnetic glass particles \n93% Isopropanol \n
1 HIV-1 v2.0 CS2 1 x 48 Tests\n(HIV-1 Lysis Reagent Cassette)\nSodium citrate dehydrate \n42.5% Guanidine thiocyanate \n< 14% Polydocanol \n0.9% Dithiothreitol\n
1 HIV-1 v2.0 CS3 1 x 48 Tests\nHIV-1 Multi-Reagent Cassette containing:\nPase \n(Proteinase Solution)\nTris buffer \n< 0.05% EDTA \nCalcium chloride \nCalcium acetate \n&#8804;7.8% Proteinase \nGlycerol 1 x 3.8 mL\n
1 EB 1 x 7.0 mL\n(Elution Buffer)\nTris-base buffer\n0.2% Methylparaben \n
1 HIV-1 v2.0 CS4 1 x 48 Tests\nHIV-1 Test-Specific Reagent Cassette containing: \n
1 HIV-1 QS 1 x 3.6 mL\n(HIV-1 Quantitation Standard)\nTris-HCl buffer\nEDTA\n< 0.005% Poly rA RNA (synthetic)\n< 0.001% Armored HIV-1 RNA construct containing\nHIV-1 primer binding sequences and a unique\nprobe binding region\n0.05% Sodium azide
1 HIV-1 MMX 1 x 2.5 mL\n(HIV-1 Master Mix)\nTricine buffer\nPotassium acetate\nPotassium hydroxide\n20% Dimethylsulfoxide\nGlycerol\n< 0.04% dATP, dCTP, dGTP, dUTP, dTTP\n< 0.003% Upstream and downstream primers to the\ngag and the LTR region of HIV-1\n< 0.003% Oligonucleotide aptamer\n< 0.003% Fluorescent-labeled oligonucleotide probes\nspecific for HIV-1 and the HIV-1 Quantitation\nStandard\n< 0.05% Z05 DNA Polymerase (microbial)\n< 0.1% AmpErase (uracil-N-glycosylase) enzyme\n(microbial)\n0.09% Sodium azide
1 CAP/CTM Mn2+ 1 x 19.8 mL\n(CAP/CTM Manganese Solution)\n< 0.5% Manganese acetate\nGlacial acetic acid\n0.09% Sodium azide
1 HIV-1 H(+)C, v2.0 4 x 1.0 mL\n(HIV-1 High Positive Control, v2.0)\n< 0.001% Armored HIV-1 RNA construct containing\nHIV-1 sequences \nNegative Human Plasma\n0.1% ProClin&reg; 300 preservative
1 HIV-1 L(+)C, v2.0 4 x 1.0 mL\n(HIV-1 Low Positive Control, v2.0)\n< 0.001% Armored HIV-1 RNA construct containing\nHIV-1 sequences.\nNegative Human Plasma\n0.1% ProClin&reg; 300 preservative
1 CTM (–) C 4 x 1.0 mL\n[COBAS&reg; TaqMan&reg; Negative Control (Human Plasma)]\nNegative Human Plasma\n0.1% ProClin&reg; 300 preservative